Dr Neil Dixon (MChem, PhD) - personal details
Dr Neil Dixon received his PhD for investigating drug-protein interactions of the Vacuolar (H+)-ATPase transmembrane protein, using a combination of synthetic chemistry, biochemistry and biophysical techniques from the University of Leeds. During this time he also took a three-month secondment at the Max-Planck Institut für Biophysical Chemie in Göttingen, Germany.
As a PDRA at the University of Manchester, he was a leading scientist on a chemical biology project, where he re-engineered the naturally occurring RNA-based regulatory control components, riboswitches, to provide novel orthogonal tools for genetic regulation [Dixon et al PNAS 2010]. These regulatory elements have been coupled to a range of reporter proteins and other functional proteins (e.g. T7 RNAP). Currently he is involved in the development and demonstration of this novel gene expression technology for use in the bio-manufacture of human therapeutic proteins (biopharmaceuticals).
He has authored 14 peer-reviewed research articles, and is a named co-inventor on UK and international patent applications. He has recently been supported through the BBSRC/RSE Enterprise Fellowship scheme (2010-2011), and is named as a Co-Investigator within an ongoing BBSRC Follow on Fund, Research Grant (BB/J019089/1), ‘Feasibility and Benchmarking of RiboTite gene expression control technology’.
He is interested in developing novel gene expression tools to provide a) higher order synthetic biology systems and devices, b) tuneable periplasmic secretion systems, c) a modular co-expression platform, and, d) metabolic feedback sensing, to aid pathway flux engineering, co-expression challenges and bioprocess optimization.
He was most recently awarded the BBSRC David Phillips Fellowship entitled “Development and Application of Next Generation Synthetic Biology Tools”<